Whats New at V3 - Akcea Therapeutics

August 16, 2019

Here's a quick look at

what we've been up to...

Akcea Therapeutics

 

Akcea, are on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines. 

 

Familial chylomicronemia syndrome (FCS) is a serious and rare lipid disorder characterized by the build-up of chylomicrons (chylomicronemia), a large lipoprotein particle that transport dietary fat and cholesterol in the body. Because chylomicrons are rich in triglycerides, people with FCS have extremely high levels of triglycerides, often reaching 10 to 20 times the normal level. People with FCS cannot break down chylomicrons, so their blood can appear milky in color (lipemic). There are approximately 3,000 to 5,000 patients with FCS worldwide. - Click here to go to their website

 

The Pop up banner was printed here at V3

 

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Summer new look for refreshing your branding?

July 10, 2017

1/5
Please reload

Recent Posts
Please reload

Archive